Unverified50% confidenceFactExact time
Regulators (such as the U.S. FDA and China's NMPA) typically require prospective data, or at least rigorously designed multicenter retrospective validation, for high-risk diagnostic AI.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/22/2026
First Seen
Valid until: 1/20/2027
Sources
Related Entities
Related Claims
UnverifiedIn sensitive domains such as healthcare and law, high-risk predictions must have a human review step.75% similarUnverifiedThe EU MDR classifies diagnostic AI as a high-risk medical device requiring notified body involvement; China's NMPA manages AI-assisted diagnostic software as Class III medical devices and requires clinical trial data.75% similarUnverified医学AI临床验证的性能基准须针对目标人群建立，不能直接沿用公开数据集的评测结果，需通过多中心前瞻性研究证明安全性和有效性72% similarUnverified在医疗诊断中召回率可能比精确率更重要，在推荐系统中需要考量 NDCG 等排序指标72% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1086554API
curl https://kongchang.com/api/v1/knowledge/claims/1086554MCP
get_claim(id=1086554)